ATE413868T1 - Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin - Google Patents

Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin

Info

Publication number
ATE413868T1
ATE413868T1 AT04798662T AT04798662T ATE413868T1 AT E413868 T1 ATE413868 T1 AT E413868T1 AT 04798662 T AT04798662 T AT 04798662T AT 04798662 T AT04798662 T AT 04798662T AT E413868 T1 ATE413868 T1 AT E413868T1
Authority
AT
Austria
Prior art keywords
hydrofluoralkan
formulation containing
spray formulation
pharmaceutical spray
acylated cyclodextrin
Prior art date
Application number
AT04798662T
Other languages
German (de)
English (en)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE413868T1 publication Critical patent/ATE413868T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT04798662T 2003-11-26 2004-11-24 Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin ATE413868T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds

Publications (1)

Publication Number Publication Date
ATE413868T1 true ATE413868T1 (de) 2008-11-15

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798662T ATE413868T1 (de) 2003-11-26 2004-11-24 Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin

Country Status (23)

Country Link
US (1) US20070104652A1 (https=)
EP (1) EP1708679B1 (https=)
JP (1) JP4950666B2 (https=)
KR (1) KR20060118509A (https=)
CN (1) CN100592908C (https=)
AT (1) ATE413868T1 (https=)
AU (1) AU2004294775B2 (https=)
BR (1) BRPI0416992A (https=)
CA (1) CA2546441C (https=)
CY (1) CY1108753T1 (https=)
DE (1) DE602004017783D1 (https=)
DK (1) DK1708679T3 (https=)
ES (1) ES2314469T3 (https=)
IL (1) IL175659A (https=)
MX (1) MXPA06005643A (https=)
NO (1) NO20062969L (https=)
NZ (1) NZ547355A (https=)
PL (1) PL1708679T3 (https=)
PT (1) PT1708679E (https=)
SE (1) SE0303179D0 (https=)
SI (1) SI1708679T1 (https=)
WO (1) WO2005053637A2 (https=)
ZA (1) ZA200604330B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
WO2023127219A1 (ja) * 2021-12-28 2023-07-06 リンテック株式会社 シリコーン系粘着剤、粘着シートおよび両面粘着シート

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
CA2546441A1 (en) 2005-06-16
CA2546441C (en) 2011-11-22
IL175659A0 (en) 2006-09-05
WO2005053637A3 (en) 2007-06-28
DE602004017783D1 (de) 2008-12-24
CN100592908C (zh) 2010-03-03
NZ547355A (en) 2009-05-31
CN101087600A (zh) 2007-12-12
US20070104652A1 (en) 2007-05-10
KR20060118509A (ko) 2006-11-23
NO20062969L (no) 2006-08-25
JP4950666B2 (ja) 2012-06-13
IL175659A (en) 2010-02-17
SI1708679T1 (sl) 2009-04-30
AU2004294775B2 (en) 2007-12-20
AU2004294775A1 (en) 2005-06-16
ES2314469T3 (es) 2009-03-16
EP1708679A2 (en) 2006-10-11
DK1708679T3 (da) 2009-02-16
MXPA06005643A (es) 2006-08-17
PT1708679E (pt) 2008-12-29
CY1108753T1 (el) 2014-04-09
HK1108390A1 (zh) 2008-05-09
WO2005053637A2 (en) 2005-06-16
JP2007515401A (ja) 2007-06-14
ZA200604330B (en) 2007-11-28
BRPI0416992A (pt) 2007-02-06
PL1708679T3 (pl) 2009-04-30
SE0303179D0 (sv) 2003-11-26
EP1708679B1 (en) 2008-11-12

Similar Documents

Publication Publication Date Title
ATE496064T1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
IL169469A (en) Folic acid derivatives containing disulfide bonds, their pharmaceutical compositions and their use
CY2016024I1 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
BRPI0509827A (pt) nanopartìculas pegiladas para transporte de moléculas biologicamente ativas, composição farmacêutica, liofilizato constituindo nanopartìculas pegiladas e processo de preparação de nanopartìculas pegiladas
NZ534040A (en) Metered dose inhaler
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
TWI315203B (en) Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
NO20090554L (no) Farmasoytiske preparater av memantin
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
WO2001066601A8 (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
CY1110664T1 (el) Ενδορινικες συνθεσετς
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
WO2005025500A3 (en) Process for preparing water soluble diterpenes and their applications
WO2006089993A3 (es) Procedimiento de obtención de hidrogeles de ciclodextrinas con glicidiléteres, las composiciones obtenidas y sus aplicaciones
WO2023001248A9 (zh) 一种含抗trop2抗体药物偶联物的药物组合物及其用途
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
WO2003063824A3 (en) Pharmaceutical composition
WO2007060512A3 (en) Compositions containing topical active agents and pentylene glycol
ATE413868T1 (de) Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin
NO20076120L (no) Stabile nanopartikkelformuleringer
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1708679

Country of ref document: EP